{"id":798673,"date":"2025-01-07T16:13:25","date_gmt":"2025-01-07T21:13:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-01-07T16:13:25","modified_gmt":"2025-01-07T21:13:25","slug":"vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BRISBANE, Calif., Jan.  07, 2025  (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 \u2013 16, 2025. The management team will also participate in one-on-one investor meetings.<\/p>\n<p>\n        <strong><br \/>\n          <u>Presentation Details:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Date: Monday, January 13, 2025 <br \/>Time: 4:30 PM PST <br \/>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JCE6pvTk2wDBw1_tJthE0Cs6oBFqgqXlN0ONdB8sPbstEJkEMpaWlpZeguWlxZg7xWOopYJdJ6_kjn_51AHgZ77yIvxbJwKN74mOcmVlnTzVqRvjiZ0uzQYY-elf_kk08VSt3HKnnTi6Wdc0zt_YXpXv7bDUIj6g2IEng9JqlxxNRv-BdTFBicpVmmCfxEA7fpTVnMVKLlDnKBSPdouuRUCYwftZs7v7vfZ5yGkbozgLtXvcOqt4bMjYTiFmifxxzZeLZot-5UMrzK3NcUKj4g==\" rel=\"nofollow\" target=\"_blank\">https:\/\/jpmorgan.metameetings.net\/events\/healthcare25<\/a><\/p>\n<p>A replay of the event will be available for 90 days and can be accessed by visiting the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PKLr2cEWOpSThde_Q4noui_7hi-DrIBx78Lu-nUNVDIkqNkJdwO5wAwIAu0HpWiQlQbV9hzXyLIH5mjykMqkIIjRdEHMwmx7jzS9byDnkHSAYaUYGSEYNrUgzarmh3Rqf_S1K5bXd2GCEAcBroMirYt6gbjC7eZdPXuRZwkhsXdEqFhOFh3qYJQAJOOZr_qvjz39mD_ZVNpRKJ8muaIhkD8WAxeuG1P6YYrYXq3V_Sz1laMaAKk-HDUggNxcHvIlXMg4VDCLRDuJMXOCQveZS6Tw96y1_wP263PhE1g1Cz8=\" rel=\"nofollow\" target=\"_blank\">Investor Calendar<\/a>\u201d section of the Vera Therapeutics website.<\/p>\n<p>\n        <strong>About Vera<\/strong><br \/>\n        <br \/>Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera\u2019s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera\u2019s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger\u2019s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QWAPJl66k2J24lbC9iNuQpzKSGgiHhBn-l-JyYFA-yvp9vn75KtIP7c4gN8Kp-0gDq0eYEbBjURlY5kjxRzRczzgOaBXuLBqKz2Hagi3PM-J6zMCTVJx8kXG5uwCUkMer10hAVpcuPngHiZ1LHg10bFMztvLq3gt-YHpLM0LPWF9bOnZpn7x6cVXy_QXAfUbW2OeEAC-pdVl_br8aRDkR2aBSPvWnwjrMGBREc1YbvM=\" rel=\"nofollow\" target=\"_blank\">www.veratx.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>For more information, please contact:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors<br \/>212-915-2569<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PzCK_zOfLmrqO9V-DKBtCGB2_Zuxcs3pMsXx6FoAFW5JYNwN3EsLH64_R71V_vVN-UqA44LGPim5xC85zSEsOpw6JogeC1-fDnQSnNgyGzXfwtwz9iidK8lZXpX4X6LF\" rel=\"nofollow\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Madelin Hawtin<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6qn_uA8TFO5iWC08Bk4o4J_oIMwGI9YiY31Nw93lENEZ17vV9w6lL6a3s5b3u0xjCJYdiIGOsHxrE4ybkFaltYqoNEMYNzfcwOwKpKfs6vo=\" rel=\"nofollow\" target=\"_blank\">MHawtin@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTU1NDZiZjktYWY4Mi00NDAwLWFmNDItYTQwZGM2MmUzNmM2LTEyMTkwMjI=\/tiny\/Vera-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 \u2013 16, 2025. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Monday, January 13, 2025 Time: 4:30 PM PST Webcast: https:\/\/jpmorgan.metameetings.net\/events\/healthcare25 A replay of the event will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. About Vera Vera Therapeutics is a late clinical-stage biotechnology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798673","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 \u2013 16, 2025. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Monday, January 13, 2025 Time: 4:30 PM PST Webcast: https:\/\/jpmorgan.metameetings.net\/events\/healthcare25 A replay of the event will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. About Vera Vera Therapeutics is a late clinical-stage biotechnology &hellip; Continue reading &quot;Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T21:13:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-01-07T21:13:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\",\"datePublished\":\"2025-01-07T21:13:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company\u2019s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 \u2013 16, 2025. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Monday, January 13, 2025 Time: 4:30 PM PST Webcast: https:\/\/jpmorgan.metameetings.net\/events\/healthcare25 A replay of the event will be available for 90 days and can be accessed by visiting the \u201cInvestor Calendar\u201d section of the Vera Therapeutics website. About Vera Vera Therapeutics is a late clinical-stage biotechnology &hellip; Continue reading \"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T21:13:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference","datePublished":"2025-01-07T21:13:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/","name":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=","datePublished":"2025-01-07T21:13:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODA2NyM2NjgzMDg0IzIyMDc0Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798673"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}